- 作者：Manel Sabat茅 ; Sergio C谩novas ; Eulogio Garc铆a ; Rosana Hern谩ndez Antol铆n ; Luis Maroto ; Jos茅 Mar铆a Hern谩ndez ; Juan H. Alonso Briales ; Antonio J. Mu帽oz Garc铆a ; Enrique Guti茅rrez-Iba帽es ; Jorge Rodr铆guez-Roda ; collaborators of the TAVI National Group
- 关键词：TAVI ; transcatheter aortic valve implantation
- 刊名：Revista Española de Cardiología (English Edition)
- 出版年：December, 2013
- 年：2013
- 卷：66
- 期：12
- 页码：949-958
- 全文大小：280 K
Introduction and objectives
The treatment of severe symptomatic aortic stenosis has been revolutionized by the technique of transcatheter valve replacement. The purpose of this study was to present the outcomes and predictors of mortality in patients enrolled between 2010 and 2011 in the Transcatheter Aortic Valve Replacement National Registry.Methods
We collected 131 preprocedural, 31 periprocedural, and 76 follow-up variables, and analyzed the immediate implant success rate, the 30-day safety endpoint, and all-cause 30-day and mid-term (mean follow-up, 244 days) mortality.
Results
From January 2010 to December 2011, a total of 1416 patients were included: 806 with Edwards valves and 610 with CoreValves. The implant success and 30-day mortality rates were 94% and 8%, respectively, without differences between types of valves and approaches. The 30-day safety endpoint and mid-term mortality rates were 14% and 16%, respectively, which were also similar between groups. The presence of comorbidities (renal failure, peripheral vascular disease, ejection fraction, and atrial fibrillation), the need for conversion to surgery, and at least moderate aortic regurgitation after transcatheter aortic valve implantation were identified as independent predictors of in-hospital and mid-term mortality.
Conclusions
The prognosis of valve implant patients could be improved by including comorbidities in patient selection and by minimizing the degree of residual aortic regurgitation to optimize the results of the procedure.